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S U M M A R Y
Objectives: To evaluate whether maternal HIV disease severity during pregnancy is associated with an
increased likelihood of lower respiratory tract infections (LRTIs) in HIV-exposed, uninfected infants.
Methods: HIV-exposed, uninfected, singleton, term infants enrolled in the NISDI Perinatal Study, with
birth weight >2500 g were followed from birth until 6 months of age. LRTI diagnoses, hospitalizations,
and associated factors were assessed.
Results: Of 547 infants, 103 (18.8%) experienced 116 episodes of LRTI (incidence = 0.84 LRTIs/100 child-
weeks). Most (81%) episodes were bronchiolitis. Forty-nine (9.0%) infants were hospitalized at least once
with an LRTI. There were 53 hospitalizations (45.7%) for 116 LRTI episodes. None of these infants were
breastfed. The odds of LRTI in infantswhosemothers had CD4%<14 at enrollmentwere 4.4 times those of
infants whose mothers had CD4% 29 (p = 0.003). The odds of LRTI in infants with a CD4+ count (cells/
mm3) <750 at hospital discharge were 16.0 times those of infants with CD4+ 750 (p = 0.002). Maternal
CD4+ decline and infant hemoglobin at the 6–12 week visit were associated with infant LRTIs after 6–12
weeks and before 6 months of age.
Conclusions: Acute bronchiolitis is common and frequently severe among HIV-exposed, uninfected
infants aged 6 months or less. Lower maternal and infant CD4+ values were associated with a higher risk
of infant LRTIs. Further understanding of the immunological mechanisms of severe LRTIs is needed.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In utero exposure to the human immunodeﬁciency virus (HIV)
may adversely affect the exposed infant’s immune system
development, possibly due to exposure to HIV proteins or even
HIV particles during fetal life,1,2 maternal and/or fetal cytokine§ Presented in part at the Pediatric Academic Societies and Asian Society for
Pediatric Research Joint Meeting, May 2–6, 2008, Honolulu, Hawaii, USA; abstract
285 (E-PAS2008:634467.7).
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doi:10.1016/j.ijid.2010.01.006imbalance,3 and/or the known inhibition of bone marrow function
by antiretrovirals.4 Qualitative differences in T cell function1,5,6
and cell-mediated immune responses to unrelated antigens7 in
HIV-exposed, uninfected infants are consistent with immunosup-
pressive effects of in utero HIV exposure, and may persist over
time.8 However, the clinical signiﬁcance of these observations has
not been completely explored.
We recently described infectious diseasemorbidity amongHIV-
exposed but uninfected infants from Latin America and the
Caribbean during the ﬁrst 6 months of life.9 In the current analysis,
we characterize LRTI episodes experienced by HIV-exposed,
uninfected infants enrolled in the NICHD International Site
Development Initiative (NISDI) Perinatal Study and assess riskses. Published by Elsevier Ltd. All rights reserved.
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ﬁrst 6 months of life. We hypothesized that, after controlling for
confounders, maternal clinical HIV disease severity and degree of
immunosuppression during pregnancy would increase the likeli-
hood of occurrence of and hospitalization for LRTIs in this
population.
2. Materials and methods
2.1. NISDI perinatal study
The NISDI Perinatal Study is a prospective cohort study of HIV-
infectedwomen and their infants at clinical sites in Argentina, the
Bahamas, Brazil, Jamaica,Mexico, and Peru.10 Enrollment began in
September 2002 and is ongoing. All enrolled women had to have
access to both antiretroviral prophylaxis and alternatives to
breast milk. HIV-infected women were enrolled into the study
during pregnancy, and followed until 6 months postpartum. A
medical history was obtained, and a physical examination was
conducted at each visit. Laboratory studies were conducted at
most visits. Their infants were evaluated prior to hospital
discharge following birth, at 6–12 weeks, and at 6 months of
age. At each infant study visit, a medical history was obtained, a
physical examination (with assessments of growth and of
morbidity) was performed, and laboratory studies (ﬂow cyto-
metry and HIV diagnostic assays, hematology and biochemical
assays) were performed. As part of the interval history, informa-
tion was collected regarding infant signs and symptoms,
diagnoses, medications, and hospitalizations. Although not
required by the NISDI protocol, infants were usually followed
monthly at the study sites to assess growth and morbidity.
Further, when an infant became ill, mothers were advised to seek
medical attention at the clinical site and, if medical attention was
obtained, clinical, radiographic, and/or laboratory documentation
was available at the site. Otherwise, when medical care was
obtained at another clinical center, the medical records were
requested. Diagnoses were reported at each site by the site
clinician. Criteria used by all sites for the diagnosis of speciﬁc
diseases were those developed for the NISDI.
Infants were considered HIV-uninfected if they had: (1) two or
more negative HIV virologic assays (e.g., HIV culture or HIV DNA
PCR), with one test performed at age 1 month or older and one
performed at age 4months or older, and no positive virologic tests;
(2) one positive HIV virologic assay followed by two negative HIV
virologic tests (with at least one performed after age 4 months); or
(3) two negative HIV antibody test results, with at least one
performed after age 6 months.
2.2. Study population and deﬁnitions
The study population comprised singleton, term (>37 com-
pleted weeks of gestation), HIV-exposed but uninfected infants
enrolled in the NISDI Perinatal Study as of March 1, 2006, who
weighed >2500 g at birth and completed 6 months of follow-up.
Infants with severe underlying cardiovascular or pulmonary
conditions were excluded from this analysis. Due to the small
numbers of subjects enrolled in other countries, the analysis was
restricted to infants born to women enrolled in Brazil and
Argentina.
An LRTI was deﬁned as having occurredwhen either a deﬁnitive
or a presumptive diagnosis of an LRTI was recorded. An infection
was considered incident if the infant had been free of any signs and
symptoms consistent with the same LRTI for at least 7 days prior to
the incident event. Due to possible overlap in clinical diagnoses of
bronchiolitis and bronchitis in this age group, these two diagnoses
were categorized as ‘bronchiolitis’.Disease severity was ascertained based on the severity of
bronchospasm and/or dyspnea occurring within 5 days of the
diagnosis of an LRTI. An infant was classiﬁed as having severe
disease if he/she presented with grade 3 dyspnea and/or grade
3 bronchospasm.11 Infant hemoglobin values for age were
classiﬁed as normal or abnormal (grade 1) according to
established criteria.11
Infant gestational age at birth (completed weeks) was deter-
mined by obstetrical estimation or by pediatric newborn exam.
Growth standard reference values were used for categorizing
subjects’ weight for age at birth.12 Maternal clinical disease staging
was performed with the use of the Centers for Disease Control and
Prevention classiﬁcation system.13 Considering that immuniza-
tions against Haemophilus inﬂuenzae type b would only be
completed by 6 months of age, and that Streptococcus pneumoniae
immunization was not mandatory in the vaccination guidelines of
either country, these immunizations were not taken into
consideration in the evaluation of risk factors for LRTI. None of
the infants received respiratory syncytial virus (RSV) prophylaxis.
2.3. Statistical analysis
The primary outcomes of interest were occurrence of and
hospitalizations due to LRTIs. Frequencies of LRTIs were calculated
according to the age at the initial diagnosis. Further, in order to
analyze the occurrence of LRTIs in relation to immunologic (CD4+)
and other (hemoglobin) laboratory indicators, data were analyzed
according to LRTI events occurring after a study visit. Thus, two
main study periods were analyzed: after hospital discharge
(including the neonatal period and post-neonatal LRTI events
occurring before the 6–12 week visit) and LRTIs occurring after the
6–12 week visit. By analyzing the data this way, we guaranteed
that outcomes (LRTIs) occurred after potential risk factors
occurred. Infant CD4+ decline was calculated by estimating Z-
scores for the distribution of the entire NISDI study population at
birth and at the 6–12 week visit. Decline was deﬁned as a negative
value of the Z-scorewhen subtracting the Z-score value at the 6–12
week visit from that at the hospital discharge visit. Maternal CD4+
decline was estimated by subtracting the Z-score at hospital
discharge from that at enrollment.
Incidence rates were calculated using person-weeks as the
denominator, and the 95% conﬁdence intervals (95% CI) were
calculated using Fisher’s exact method. Proportions were estimat-
ed, and 95% CIs for proportions were calculated using the exact
binomial method. Associations of categorical variables with LRTIs
before and after the 6–12 week visit were evaluated using the
Fisher–Freeman–Halton exact test. Variables at least marginally
associated with LRTIs (p  0.20) were considered candidates for
the multivariable logistic regression modeling. Both stepwise
selection and backward elimination strategies were applied to
determine whether both selection procedures arrived at the same
parsimonious model (using a 5% signiﬁcance level).
3. Results
3.1. Derivation and characteristics of the study population
As of March 2006, a total of 988 HIV-infected pregnant women
had been enrolled into the NISDI Perinatal Study, of whom 910
were enrolled in Argentina or Brazil. Of these enrollments, 877
(96.4%) represented the ﬁrst enrollment into the study. These 877
women delivered 794 singleton, live born infants. Birth data were
not available for eight infants. Of the remaining 786 infants, 707
(89.9%) were followed through the 6-month study visit. Among
these 707 infants, seven were HIV-infected, 25 were of indetermi-
nate HIV infection status, and 675 were HIV-uninfected. Of these
Table 1
Characteristics of the study population (N=547) and risk of LRTI before and after the 6–12 week visit
Before the 6–12 week visita After the 6–12 week visit
Characteristic N=547 LRTI Univariate pb LRTI Univariate pb
(n=23 (4.2%)) OR (95% CI) (n=85 (15.5%)) OR (95% CI)
n (%) n (%)
Maternal country of residence
Brazil 378 (69.1) 13 (3.4) 1 0.2 62 (16.4) 1 0.4
Argentina 169 (30.9) 10 (5.9) 1.8 (0.8–4.1) 23 (13.6) 0.8 (0.5–1.4)
Maternal age at delivery (years)
<20 30 (5.5) 1 (3.3) 0.8 (0.1–6.5) 0.9 7 (23.3) 1.6 (0.7–4.0)
20–29 320 (58.7) 13 (4.1) 1 50 (15.6) 1
>29 195 (35.8) 9 (4.6) 1.1 (0.5–2.7) 28 (14.4) 0.9 (0.6–1.5)
Missing 2 0 0
Maternal education (years)
13 20 (3.7) 0 (0) 1 0.50 1 (5) 1 0.29
7–12 344 (62.9) 13 (3.8) NA 51 (14.8) 3.3 (0.4–25.2)
0–6 183 (33.5) 10 (5.5) NA 33 (18.0) 4.2 (0.5–32.3)
Gainful employment outside of the home
Yes 121 (22.1) 2 (1.7) 1 0.13 22 (18.2) 1 0.39
No 426 (77.9) 21 (4.9) 3.1 (0.7–13.4) 63 (14.8) 0.8 (0.5–1.3)
Number of persons in the household
1–3 245 (44.8) 6 (2.4) 1 0.09 36 (14.7) 1 0.6
4 302 (55.2) 17 (5.6) 2.4 (0.9–6.1) 49 (16.2) 1.1 (0.7–1.8)
Maternal CD4+ count at enrollment (cells/mm3)
500 174 (32.4) 8 (4.6) 1 0.5 24 (13.8) 1 0.63
200–499 302 (56.2) 11 (3.6) 0.8 (0.3–2.0) 51 (16.9) 1.3 (0.8–2.2)
<200 61 (11.4) 4 (6.6) 1.5 (0.4–5.0) 8 (13.1) 0.9 (0.4–2.2)
Missing 10 0 2
Maternal CD4% at enrollment
<14 32 (6.5) 4 (12.5) 2.7 (0.8–9.1) 0.07 3 (9.4) 0.7 (0.2–2.3) 0.60
14–28 219 (44.4) 7 (3.2) 0.6 (0.2–1.6) 35 (16.0) 1.2 (0.7–2.0)
29 242 (49.1) 12 (5.0) 1 33 (13.6) 1
Missing 54 0 14
Maternal CD4+ count at hospital discharge (cells/mm3)
500 222 (43.7) 9 (4.1) 1 0.59 31 (14.0) 1 0.49
200–499 243 (47.8) 9 (3.7) 0.9 (0.4–2.3) 44 (18.1) 1.4 (0.8–2.3)
<200 43 (8.5) 3 (7.0) 1.8 (0.5–6.8) 7 (16.3) 1.2 (0.5–2.9)
Missing 39 2 3
Maternal CD4% at hospital discharge
<14 26 (5.5) 2 (7.7) 2.0 (0.4–9.7) 0.52 4 (15.4%) 1 0.49
14–28 167 (35.4) 8 (4.8) 1.2 (0.5–3.1) 27 (16.2%) 1.4 (0.8–2.3)
29 279 (59.1) 11 (3.9) 1 42 (15.1%) 1.2 (0.5–2.9)
Missing 75 2 12
Maternal CD4+ decline
No 259 (51.8) 12 (4.6) 1 0.7 35 (13.5) 1 0.14
Yes 241 (48.2) 9 (3.7) 0.8 (0.3–1.9) 45 (18.7) 1.5 (0.9–2.4)
Missing 47 2 5
Maternal plasma viral load at enrollment (copies/ml)
<1000 314 (58.6) 13 (4.1) 1 0.8 43 (13.7) 1 0.45
1000–10 000 113 (21.1) 4 (3.5) 0.8 (0.3–2.7) 20 (17.7) 1.4 (0.8–2.4)
10 000 109 (20.3) 6 (5.5) 1.3 (0.5–3.6) 19 (17.4) 1.3 (0.7–2.4)
Missing 11 0 3
Maternal plasma viral load at hospital discharge (copies/ml)
<1000 433 (84.5) 18 (4.2) 1 0.43 73 (16.9) 1 0.07
1000–10 000 51 (10.0) 1 (2.0) 0.5 (0.1–3.5) 3 (5.9) 0.3 (0.1–1.0)
10 000 28 (5.5) 2 (7.1) 1.8 (0.4–8.1) 6 (21.4) 1.3 (0.5–3.4)
Missing 35 2 3
Maternal HIV clinical stage at enrollment
A 473 (86.5) 18 (3.8) 1 0.19 75 (15.9) 1 0.87
B 34 (6.2) 3 (8.8) 2.4 (0.7–8.8) 4 (11.8) 0.7 (0.2–2.1)
C 40 (7.3) 2 (5) 1.3 (0.3–6.0) 6 (15) 0.9 (0.4–2.3)
Maternal HIV clinical stage at hospital discharge
A 472 (86.3) 18 (3.8) 1 0.23 75 (15.9) 1 0.84
B 35 (6.4) 3 (8.6) 2.4 (0.7–8.4) 4 (11.4) 0.7 (0.2–2.0)
C 40 (7.3) 2 (5) 1.3 (0.3–5.9) 6 (15) 0.9 (0.4–2.3)
Gender
Female 261 (47.7) 9 (3.4) 1 0.52 34 (13.0) 1 0.1
Male 286 (52.3) 14 (4.9) 1.4 (0.6–3.4) 51 (17.8) 1.4 (0.9–2.3)
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Table 1 (Continued )
Before the 6–12 week visita After the 6–12 week visit
Characteristic N=547 LRTI Univariate pb LRTI Univariate pb
(n=23 (4.2%)) OR (95% CI) (n=85 (15.5%)) OR (95% CI)
n (%) n (%)
Weight for age percentile at birth
5th 531 (97.1) 23 (4.3) 1 1.00 82 (15.4) 1 0.7
<5th 16 (2.9) 0 NA 3 (18.8) 1.3 (0.4–4.5)
Infant CD4+ count at hospital discharge (cells/mm3)
<750 8 (1.8) 2 (25) 10.2 (1.9–4.9) 0.03 0 (0) NA 1.0
750 441 (98.2) 14 (3.2) 1 85 (19.3) 1
Missing 98 7 0
Infant CD4% at hospital discharge
15–24 4 (1.0) 1 (25) 8.8 (0.9–89.7) 0.15 0 (0) NA 1.0
25 411 (99.0) 15 (3.6) 1 77 (18.7) 1
Missing 132 7 8
Infant CD4+ count at 6–12 week visit (cells/mm3)
<750 7 (1.5) 0 (0) NA 0.36
750 451 (98.5) 85 (18.8) 1
Missing 89 0
Infant CD4% at 6–12 week visit
<25 126 (25.4) 27 (21.4) 1.5 (0.9–2.6) 0.1
25 386 (74.6) 58 (15.0) 1
Missing 35 0
Infant CD4+ decline
Yes 48 (12.3) 11 (22.9) 1.6 (0.8–3.3) 0.2
No 342 (87.7) 54 (15.8) 1
Missing 157 20
Infant hemoglobin at hospital discharge
Normal 353 (76.1) 13 (3.7) 1 1.00 52 (14.7) 1 0.10
Abnormal 111 (23.9) 4 (3.6) 1.0 (0.31–3.1) 24 (21.6) 1.6 (0.9–2.7)
Missing 83 6 9
Infant hemoglobin at 6–12 week visit
Normal 341 (72.4) 40 (11.7) 1 <0.001
Abnormal 130 (27.6) 43 (33.1) 3.7 (2.3–6.1)
Missing 76 2
LRTI, lower respiratory tract infection; OR, odds ratio; CI, conﬁdence interval; NA, not applicable (OR not calculated due to 0 value in a cell).
a Grayed area indicates that values are not applicable for this age group.
b p-Value using Fisher–Freeman–Halton exact test.
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weeks and a birth weight of 2500 g. A total of 16 infants were
excluded from the analysis due to underlying severe cardiovascu-
lar (n = 12; pulmonary valve stenosis, tricuspid valve insufﬁciency,
ventricular septal defect, patent ductus arteriosus, foramen ovale)
or pulmonary conditions (n = 5; pulmonary hypertension, meco-
nium aspiration); one infant had both cardiovascular and
pulmonary conditions. Thus, a total of 547 infants were eligible
for this analysis and contributed 13 734 person-weeks of follow-up
time. Adherence to study visits at 6–12weeks and at 6monthswas
100%. The average number and range of days between laboratory
assessments and the occurrence of the LRTI were: hemoglobin
mean 62 days (4–138) and CD4 cell count mean 32 days (2–140).
The main characteristics of the study population are shown in
Table 1. Most infants were from Brazil (69.1%). Only two infants
received any breast milk. All infants received HIV perinatal
transmission prophylaxis with zidovudine (median duration 44
days). Some mothers reported substance use during pregnancy
(tobacco (22.1%), alcohol (9.3%), marijuana (2.2%), cocaine (2.7%)).
All of them used antiretrovirals during pregnancy either as
prophylaxis (58.7%) or treatment (41.3%). Most children (97.1%)
were above the 5th percentile of weight for age, and 16 (2.9%)
weighed exactly 2500 g. In univariate analysis, only infant CD4
count at hospital discharge was signiﬁcantly associated with LRTI
before the 6–12week visit, and infant hemoglobin at the 6–12week
visitwas signiﬁcantly associatedwith LRTI after the 6–12weekvisit.3.2. Occurrence of and hospitalization for LRTIs
Of 547 infants, 103 (18.8%) experienced 116 LRTIs with a mean
of 1.1 events per infant (Table 2). The overall incidence rate of LRTIs
was 0.84 per 100 child-weeks (95% CI 0.7–1.0). No LRTIs occurred
during the ﬁrst 6 days of life. Overall, there were 53 hospitaliza-
tions for 116 episodes of LRTI. Forty-nine of 547 (9.0%) infantswere
hospitalized at least once with an LRTI. Of 41 hospitalizations due
to bronchiolitis, the median duration of hospitalization was 5 days
(range 1–30 days). Of 12 hospitalizations due to pneumonia, the
median duration of hospitalization was 7 days (range 4–19 days).
No infant died due to an LRTI or related complications.
Ten infants had two episodes of bronchiolitis; one was
diagnosed with bronchiolitis and then pneumonia 3 weeks later,
and one was diagnosed with two different episodes of pneumonia.
Among 22 episodes of pneumonia, 16 (72.7%) had consistent
radiographic ﬁndings. The remaining six (27.3%) did not have chest
X-rays and diagnosis was based on clinical ﬁndings. In one episode
(4.5%), microbiology data conﬁrmed the etiology as being RSV.
Disease was classiﬁed as severe in 2/22 (9.1%) episodes of
pneumonia and 12/94 (12.8%) episodes of bronchiolitis. LRTIs
had a seasonal distribution (Figure 1), with most events occurring
during June and July of each year (winter in Brazil and Argentina),
and the fewest during the summer months (December, January
and February). Hospitalization occurred in 12/22 (54.5%) episodes
of pneumonia and in 41/94 (43.6%) episodes of bronchiolitis.
Table 3
Multivariable analysis of factors associated with LRTIs among infants before the 6–
12 week visit and after the 6–12 week visit
N=547 LRTI n (%) OR (95% CI) Adjusted OR
(95% CI)
Before the 6–12 week visit
Maternal CD4% at enrollment
<14 32 4 (12.5) 2.7 (0.8–9.1) 4.4 (1.2–16.0)a
14–28 219 7 (3.2) 0.6 (0.2–1.6) 0.4 (0.1–1.6)
29 242 12 (5.0) 1 1
Table 2
Incidence of LRTIs by type of LRTI and age at onset of infection
Type of LRTI Age Infants
(n)
Episodes
(n)
Cumulative incidence
per 100 childrena (95% CI)
Incidence per 100
child-weeks
(95% CI)
Hospitalizationsb
n (%)
(95% CI)
7–27 days 28 days
Episodes Hospitalizations
n (%)
Episodes Hospitalizations
n (%)
Pneumonia 2 2 (100) 20 10 (50) 20 22 3.7
(2.2–5.6)
0.16
(0.1–0.2)
12 (54.5)
(32.2–75.6)
Bronchiolitis 6 5 (83.3) 88 36 (40.9) 83 94 15.2
(12.3–18.5)
0.68
(0.5–0.8)
41 (43.6)
(33.4–54.2)
Total 8 7 (87.5) 108 46 (42.6) 103 116 18.8
(15.6–22.4)
0.84
(0.7–1.0)
53 (45.7)
(36.4–55.2)
LRTI, lower respiratory tract infection; CI, conﬁdence interval.
a (Number of infants with 1 LRTI episode/total number of infants)100.
b Episodes of hospitalization for LRTIs/number of episodes of LRTIs.
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LRTI and in 13/49 (26.5%) hospitalized infants. Among infants with
bronchiolitis and pneumonia, 12/83 (14.5%) and 2/20 (10%) had
severe disease, respectively. All children with severe disease were
hospitalized (data not shown).
3.3. Factors associated with the occurrence of LRTIs
Only eight infections occurred during the neonatal period,
which prevented separate analysis of neonatal LRTIs. With respect
to LRTIs before the 6–12 week visit, factors considered for
multivariable analyses were: maternal country of residence, the
number of persons in the household,maternal gainful employment
outside of the home, maternal CD4 percentage at enrollment,
maternal HIV clinical stage at enrollment, and infant CD4+ count
and CD4 percentage at hospital discharge following birth. Factors
associated with LRTIs before the 6–12 week visit in multivariable
analyses (Table 3) were maternal CD4 percentage at enrollment
and infant CD4+ count at hospital discharge.
In terms of LRTIs after the 6–12week visit, variables included in
multivariable analyses were: maternal CD4+ decline (from
enrollment to hospital discharge), maternal plasma viral load at
hospital discharge, infant gender, infant CD4 percentage at the 6–
12 week visit, infant CD4+ decline, and infant hemoglobin at
hospital discharge and at the 6–12week visit. Infant hemoglobin at
the 6–12 week visit and maternal CD4 decline were associated
with LRTI after 6–12 weeks (Table 3).
3.4. Factors associated with hospitalizations for LRTIs
In univariate analysis, four ormore persons in the household (OR
2.5; 95% CI 1.1–5.7) and length for age <5th percentile at birth (OR
5.9; 95%CI 1.2–28.6) were signiﬁcantly associated with hospitaliza-Figure 1. Incidence rate of LRTIs per 100 child-weeks according tomonth of the year.tion among children who had an LRTI. Also, all children with acute
dyspnea (grade 4) and bronchospasm and/or dyspnea (grade 3)
were hospitalized. We attempted to model all variables that met
inclusion criteria formodeling (i.e.,p  0.2), but after bothbackward
and forward elimination processes, no variable met the 0.05
criterion. Data were also analyzed taking into account only those
83 infants with bronchiolitis episodes, of whom 38 were hospital-
ized. A higher number of persons in the household (p = 0.04) and
bronchospasm and/or dyspnea grade 3 (p< 0.0001) were associ-
ated with hospitalization (data not shown).
4. Discussion
In this study, approximately 20% of infants (0.7–1.0/100 child-
weeks) experienced at least one episode of acute LRTI during the
ﬁrst 6 months of life. Most (81%) of these episodes were
bronchiolitis, a signiﬁcant proportion of them (45.7%) required
hospitalization, and 12.1% of the episodes presented as severe
clinical disease. After controlling for known risk factors, we found
that lower maternal and infant CD4+ values were associated with
an increased likelihood of LRTI among infants before the 6–12
week visit. Maternal CD4+ decline and infant hemoglobin at theMissing 54
Infant CD4+ count at hospital discharge (cells/mm3)
<750 8 2 (25) 10.2 (1.8–54.9) 16.0 (2.7–96.1)b
750 441 14 (3.2) 1 1
Missing 98
After the 6–12 week visit
Maternal CD4+ decline
No 259 35 (13.5) 1 1
Yes 241 45 (18.7) 1.5 (0.9–2.4) 1.7 (1.0–2.8)
Missing 47 5
Infant hemoglobin at 6–12 week visit
Normal 341 40 (11.7) 1 1
Abnormal 130 43 (33.1) 3.7 (2.3–6.1) 3.5 (2.1 – 6.0)
Missing 76 2
LRTI, lower respiratory tract infection; OR, odds ratio; CI, conﬁdence interval.
a p=0.003.
b p=0.002.
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acute LRTI among infants after the 6–12 week visit.
It has been well documented that HIV-infected infants are at
increased risk of LRTIs as compared toHIV-uninfected infants, even
if they are breastfed.14 However, it is not known whether HIV-
uninfected exposed infants are more susceptible to LRTIs than are
infants born to HIV-uninfected mothers. Limited data on respira-
tory symptoms or pneumonia episodes in African cohorts have
suggested that they occur with similar frequency in HIV-exposed
and -unexposed infants in that setting.14
Although a control group of infants born to HIV-uninfected
mothers was not available in our study, a comparison with the
most recent available data from a Brazilian community-based
study15 showed that the frequency of LRTIs in the NISDI cohort of
HIV-uninfected infants was similar to the 20% prevalence of all
respiratory tract infections (RTIs) in infants. However, this study15
did not differentiate between LRTI and upper RTI. If we
conservatively assume that RTIs in infants born to HIV-uninfected
mothers are equally distributed between LRTIs and upper RTIs, we
conclude that HIV-uninfected, exposed infants have twice as many
LRTIs as infants born to HIV-uninfected mothers. Still, taking into
account that the intensity of respiratory viral epidemics, that the
disease severity varies geographically and temporally, and that
breastfeeding reduces the risk of respiratory infections in young
infants,16 a concurrent control group of infants born to HIV-
uninfected mothers who were not breastfed from a similar
sociodemographic background would be required to address the
question of whether HIV-uninfected infants born to HIV-infected
mothers were more susceptible to LRTIs than infants born to HIV-
uninfected mothers. Due to the lack of a control group, we focused
this analysis on characterization of LRTIs and risk factors
(especially maternal HIV infection characteristics) for LRTIs.
Community-based studies have shown that acute respiratory
symptoms in otherwise healthy infants occur frequently, with
virus being identiﬁed in 70% to 80% of these episodes, including
those presenting as LRTI.17,18 Although the etiologic agents of the
LRTIs in our study subjects were usually not identiﬁed, various
factors (the young age at presentation, the characterization of the
clinical diagnosis as bronchiolitis with wheezing in the great
majority of the infants, and the occurrence of a well deﬁned
seasonal pattern with an outbreak during late autumn and winter)
suggest that most of these infections were caused by viruses. Even
those episodes characterized as pneumonia could be primarily or
secondarily related to a viral infection in these infants, since most
occurred after the peak incidence of bronchiolitis.
In our study, we restricted the analysis to otherwise healthy,
term HIV-exposed but uninfected infants. In order to test our
hypothesis, we used logistic regression analysis controlling for
socioeconomic background, household crowding, maternal tobac-
co use, maternal employment, and maternal education (which are
well-deﬁned correlates of respiratory disease among infants from
less privileged populations19). Besides abnormal infant hemoglo-
bin at the 6–12 week visit being a predictor of the occurrence of
LRTIs in infants older than 6–12 weeks, the odds of LRTI were two-
to four-fold greater among infants whose mothers had greater
immunosuppression during pregnancy. The magnitude of this
association suggests thatmaternal immunological dysfunction due
to HIV infection increases the risk of LRTI, as has been
demonstrated for overall infant morbidity9 and mortality.20
Considering further the strong association found by us between
lower infant CD4+ lymphocyte counts at birth and the occurrence
of LRTIs, our results are consistent with previously published
reports of the effects of maternal HIV infection on immune cells
numbers, maturation and/or function of exposed infants.1,5–8,21
However, the exact nature of immunological characteristics which
predispose some HIV-uninfected infants to acquire LRTIs deservesfurther investigation, including evaluation of the role of passively-
acquired speciﬁc antibodies.
In developed countries, where hospitalization data are used as a
surrogate for disease severity, the highest reported rates of
admissions for acute episodes of RSV-associated bronchiolitis range
from10% to20% forpreterm infants,with thehighest rates occurring
among those with underlying disease,22 while only approximately
3%of termornear termotherwisehealthy infants arehospitalized.23
In order to analyzewhether rates of hospitalization observed in this
study could be explained by the hospital admission practices for
HIV-uninfected infants at the research study sites due to socioeco-
nomic conditions (as indicated by general guidelines of LRTI
management in these countries24), we also evaluated disease
severity based on the occurrence of moderate or life-threatening
bronchospasm and/or dyspnea. As expected, severe disease (which
occurred among 12.6% of infants) perfectly predicted hospitaliza-
tion. Variables indicating socioeconomic status, such as years of
maternal educationormaternal gainful employment,didnotpredict
hospital admissions. However, at the univariate level, household
crowding, a circumstance usually associated with low socioeco-
nomic status andwith the occurrence and severity of LRTIs,25,26was
found to be associated with hospitalization in this cohort. Taking
into account that it was not possible to control completely for
confounders, and that two thirds of infants who were admitted did
not have severe illness, we cannot rule out whether family and
household conditions inﬂuenced the physician’s decision to
hospitalize the infant. Despite 26.5% of hospitalized infants having
severe disease, this rate is still higher than those reported for term
infants. These ﬁndings suggest that it will be important to
investigate whether the immune proﬁle of HIV-uninfected infants
predisposes them to increased LRTI severity either due to decreased
cellular immunity, low virus-speciﬁc antibodies, or increased
severity of inﬂammatory responses, as has been recently explored
for unexposed infants.27–29 The possibility of long term sequelae for
young infantswithbronchiolitis episodes30 calls further attention to
this issue.
This study is limited due to the lack of a control group of infants
born to HIV-uninfected mothers. Missing values for some key
variables, such as infant CD4 cell counts and hemoglobin values at
hospital discharge, might have decreased statistical power in
multivariable analysis.
This study demonstrates that LRTIs (primarily acute bronchiol-
itis) are common and frequently severe among HIV-exposed,
uninfected, non-breastfed Latin American infants during the ﬁrst 6
months of life. We have shown that the immunological status of
both the mother and the infant are associated with an increased
risk of LRTI during the ﬁrst 6 months of life. Further understanding
of the immunological mechanisms of severe disease may help in
avoiding sequelae and in the development of interventions.
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